Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Corporate Update (February 2023)

33 slides from Reata Pharmaceuticals's corporate update, Feb 28, 2023

  1. Slide 1: SKYCLARYS Approval Call

    SKYCLARYS™ Approval Call February 28, 2023 Exhibit 99.3

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward‐looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward‐looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Opening Remarks | Warren Huff, Chief Executive Officer SKYCLARYS Label | Colin Meyer, MD, Chief Innovation Officer SKYCLARYS PMR & Registry | Seemi Khan, MD, Chief Medical Officer SKYCLARYS Commercial Launch | Dawn Bir, Chief Commercial Officer Operational & Financial Update | Manmeet

  4. Slide 4: SKYCLARYS First and Only FDA Approved Therapy for Friedreich's Ataxia

    SKYCLARYSTM First and Only FDA Approved Therapy Indicated for Patients with Friedreich’s Ataxia 1Please see full Prescribing Information at SKYCLARYS.com; FDA: U.S. Food and Drug Administration; FA: Friedreich’s ataxia

  5. Slide 5: Looking Forward

    Looking Forward mFARS: modified Friedreich’s Ataxia Rating Scale; MAA: Marketing Authorization Application SKYCLARYS is indicated for the treatment of FA in patients aged 16 years and older No contraindications or limitations based on pes cavus, cardiovascular status, ambulation, mFARS score, or old

  6. Slide 6: SKYCLARYS Label

    SKYCLARYS Label

  7. Slide 7: Friedreich's Ataxia: Ultra-Rare, Progressive, Neuromuscular Disease

    Friedreich’s Ataxia: Ultra-Rare, Progressive, Neuromuscular Disease 1Cook A., Br Med Bull. 2017; 2Poburski D., Biology Open 2016; 3D’Oria V., Int. J. Mol. Sci. 2013; 4Paupe V., PLoS ONE 2009; 5U.S. claims data and projected diagnosed, 6Rummey C., Neurol Genet 2019; 7Rummey C., E Clinical Medicine. 2

  8. Slide 8: SKYCLARYS: Prescribing Information

    SKYCLARYS: Prescribing Information ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BNP: B-type natriuretic peptide No contraindications or restrictions based on pes cavus, ambulatory, or cardiovascular status No upper age limit or mFARS score restriction Overview of Prescribing Infor

  9. Slide 9: SKYCLARYS: Warnings and Precautions

    SKYCLARYS: Warnings and Precautions Elevation of Aminotransferases Monitor ALT, AST, and total bilirubin prior to and monthly for 3 months after initiation of treatment, and periodically thereafter If transaminases increase to levels greater than 5 times the ULN, or greater than 3 times the ULN with

  10. Slide 10: Adverse Reactions Reported in 10% or More of Patients

    Adverse Reactions Reported in 10% or More of Patients Treated with SKYCLARYS and Greater than Placebo Safety Evaluation and MOXIe Part 2 Adverse Events The safety of SKYCLARYS 150 mg once daily has been evaluated in 165 patients with FA 137 patients exposed for at least 48 weeks 125 patients exposed

  11. Slide 11: MOXIe Part 2 Study Design

    MOXIe Part 2 Study Design Scr: screening Double-blind, placebo-controlled, randomized trial (n=103) Enrolled a wide range of patients with FA aged 16 to 40 years Patients randomized 1:1 to 150 mg SKYCLARYS or placebo Primary endpoint: change from baseline in mFARS at Week 48 103 Patients Scr D1 WK12

  12. Slide 12: MOXIe Part 2 Placebo-Controlled Trial Results

    Treatment with SKYCLARYS resulted in statistically significant lower (improved) mFARS scores relative to placebo at Week 48 MOXIe Part 2 Placebo-Controlled Trial Results Data plotted are LS mean changes from baseline estimated from mixed model repeated measures (MMRM) analysis for patients randomize

  13. Slide 13: MOXIe Extension: Post Hoc Propensity-Matched Analysis

    MOXIe Extension: Post Hoc Propensity-Matched Analysis FA-COMS: Friedreich’s Ataxia Clinical Outcome Measures Study A post hoc Propensity-Matched Analysis was conducted using data from the open-label MOXIe Extension study and external natural history data from FA-COMS as a comparator FA-COMS is a glo

  14. Slide 14: SKYCLARYS Post-Marketing Requirements & Registry Study

    SKYCLARYS Post-Marketing Requirements & Registry Study

  15. Slide 15: Post-Marketing Requirements

    Post-Marketing Requirements Drug-drug interaction study Thorough QT study Lactation study (milk only) Pregnancy and lactation surveillance study Additional nonclinical studies

  16. Slide 16: SKYCLARYS: Post-Approval Registry Study

    SKYCLARYS: Post-Approval Registry Study In addition to the post-marketing requirements, Reata will sponsor a post-marketing registry study Prospective, observational, multinational study Patients with FA treated with SKYCLARYS commercially Objective is to evaluate long-term safety in the real-world

  17. Slide 17: Pharmacovigilance and Medical Affairs

    Pharmacovigilance and Medical Affairs Established infrastructure to support pharmacovigilance and safety obligations for SKYCLARYS in the U.S. Medical Information call center has been established Medical affairs team hired and trained to support SKYCLARYS launch

  18. Slide 18: SKYCLARYS Commercial Launch Plans

    SKYCLARYS Commercial Launch Plans

  19. Slide 19: Friedreich's Ataxia is a Serious, Devastating, Ultra-Rare Disease

    Friedreich’s ataxia is an ultra-rare disease Only symptomatic treatment has been available FA strikes the young and vulnerable Patients progress from independence to reliance on others Often, mobility requires wheelchair dependence within 10 years of diagnosis Friedreich’s Ataxia is a Serious, Devas

  20. Slide 20: Friedreich's Ataxia: Patients and HCPs Waiting for a Treatment

    Friedreich’s Ataxia: Patients and HCPs Waiting for a Treatment 1NIH Friedreich Ataxia Fact Sheet (Accessed 2/2023); 22023 Claims Analysis; 3Estimated addressable market; HCP: Healthcare provider US claims data indicates about 5,000 unique, diagnosed FA patients The initial estimate of the Total Addr

  21. Slide 21: Commercial Launch Strategy

    Communicate the value of SKYCLARYS to HCPs who treat FA Activate FA patients to proactively seek SKYCLARYS treatment Facilitate coverage, access and affordability Commercial Launch Strategy First and only FDA approved treatment for FA in adults and adolescents aged 16 years and older Establish SKYCL

  22. Slide 22: HCPs Treating FA Patients Identified

    HCPs Treating FA Patients Identified Commercial efforts to focus on neurology and HCPs with diagnosed patients 1CCRN: Collaborative Clinical Research Network in Friedreich’s ataxia, https://curefa.org/network; ; 2https://www.ataxia.org/neurologists-and-specialty-clinics/; 32023 FA Claims analysis A

  23. Slide 23: Neurologists Anticipate Prescribing SKYCLARYS for FA

    Approximately 95% of neurologists surveyed anticipate prescribing SKYCLARYS within 1 year of approval FA-treating PCPs also communicated that they are likely to prescribe within the first year HCPs are dissatisfied with lack of treatment options currently available to FA patients HCPs indicated that

  24. Slide 24: Reaching and Educating Patients, HCPs and Payers

    Reaching and Educating Patients, HCPs and Payers Patient & HCP Education Sales Force Efforts Patient Access Neurology Sales Team National Account Directors Patient Access Liaisons Practice-Level Access Support Centralized Hub Services HCP & Key Account Targets Neurology Sales Experience Rare Disease

  25. Slide 25: The Responsibility of Patient Access & Affordability

    www.ReataREACH.com 1-844-98-REACH No FA patient will face more than a nominal copay for SKYCLARYS treatment The Responsibility of Patient Access & Affordability 12022 claims analysis; PAP: Patient assistance program; OOP: Out of pocket Commercial Copay Support Product Distribution Insurance & Access

  26. Slide 26: Pricing SKYCLARYS

    Pricing SKYCLARYS SKYCLARYS Pricing Prioritizes Patient Access and Delivering Value to Payers and Physicians Pricing Principles Size of FA Patient Population Urgent Unmet Need for FA Patients SKYCLARYS Efficacy & Safety Profile Novel Mechanism of Action in FA Time and Financial Investment Patient Ac

  27. Slide 27: Beginning Treatment with SKYCLARYS

    Beginning Treatment with SKYCLARYS REACH Patient Access Services now active New Patient Start Forms available on the REACH website: www.reataREACH.com 1-844-98-REACH Find information about SKYCLARYS through the brand website: www.SKYCLARYS.com (Websites active within 24 hours) SKYCLARYS Commercial P

  28. Slide 28: Operational and Financial Update

    Operational and Financial Update

  29. Slide 29: Operational Update

    Operational Update Anticipate commercial drug supply to be available in the second quarter of 2023 Accelerating build up of our EU infrastructure following submission of MAA SKYCLARYS intellectual property Composition of Matter patents granted in U.S., Europe, Japan, China, and more than 20 other te

  30. Slide 30: Financial Update

    Financial Update Strong balance sheet Cash and marketable securities $387.5 million as of December 31, 2022 Option to monetize rare pediatric disease priority review voucher No outstanding funded debt Cash guidance Based on our operational plans, we reaffirm our cash guidance runway through the end

  31. Slide 31: Closing Thoughts

    Closing Thoughts

  32. Slide 32: Reata Looking Ahead in 2023

    Reata Looking Ahead in 2023 With SKYCLARYS approval Reata is transitioning into a commercial enterprise Planning to engage with FDA about possible label expansion for pediatric patients younger than 16 years of age MAA for omaveloxolone in FA submitted in 4Q22 Plan to pursue development of our Nrf2

  33. Slide 33: Q&A

    Q&A

Reata Pharmaceuticals — Corporate Update (February 2023) on 6ix